Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

NCT01144455 is registered in ClinicalTrials.gov with ImmunoGenesis as lead sponsor.

NCT NCT01144455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01144455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Lead sponsor
ImmunoGenesis
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
December 31, 2014
Enrollment
214 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma